We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




One-Step POC Diagnostic Test Based on Silicon Chip

By LabMedica International staff writers
Posted on 25 Nov 2009
A one-step point-of-care-diagnostic test, based on a silicon chip requires a very small sample volume, is rapid, portable, easy to use, and can test for many diseases, including cardiovascular disease. More...
The new diagnostic test uses capillary forces to analyze tiny samples of serum, or blood, for the presence of disease markers, which are typically proteins that can be detected in people's blood for diagnostic purposes.

The device uses integrated microfluidic elements and reagents such as detection antibodies, capture antibodies, and analyte molecules for performing one-step immunoassays. The addition of a sample triggers a cascade of events powered by capillary forces for accomplishing a sandwich immunoassay that is read using a fluorescence microscope.

IBM Research-Zurich (Switzerland) scientists Luc Gervais and Emmanuel Delamarche, in collaboration with the University Hospital of Basel (Switzerland) developed the new test. The IBM scientists encoded the forces of capillary action on a microfluidic chip made of a silicon compound, similar to those used in computer chips. The chip contains sets of micrometer wide channels through which the test sample flows in approximately 15 seconds, several times faster then traditional tests. The filling speed can be adjusted to several minutes when the chip requires additional time to read a more complex disease marker.

The diagnostic test has been studied on heart disease but the scientists believe that it could be used to diagnose any disease that markers have been developed for, such as: breast cancer, prostate cancer, lung cancer, human immunodeficiency virus (HIV), hepatitis C virus (HCV), Influenza virus (including the H1N1 strain and others), Epstein-Barr virus (EBV), and bacterial infections, such as Escherichia coli. The test works by recognizing antibodies; therefore, as long as the patient's body has begun to fight the disease by developing antibodies, it should be able to identify the disease.

Due to its small size, the chip can be embedded in several types of form factors, depending on the application, including a credit card, a pen, or something similar to a pregnancy test. Besides diagnosing diseases, the test is also sufficiently flexible to test for chemical and biohazards.

The test is described in the online version of the December 7, 2009 issue of the journal Lab on a Chip.

Related Links:
IBM Research-Zurich
University Hospital of Basel



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.